Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer

Irinotecan (CPT-11) has been shown to exhibit excellent antitumour activity against small-cell lung cancer (SCLC). A multi-institutional phase II study was therefore conducted to evaluate the efficacy and toxicity of CPT-11 combined with cisplatin (CDDP) and etoposide (ETOP) (PEI regimen) for the tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, K, Sekine, I, Nishiwaki, Y, Kakinuma, R, Kubota, K, Matsumoto, T, Ohmatsu, H, Niho, S, Kodama, T, Shinkai, T, Tamura, T, Ohe, Y, Kunitoh, H, Yamamoto, N, Nokihara, H, Yoshida, K, Sugiura, T, Matsui, K, Saijo, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364791/
https://www.ncbi.nlm.nih.gov/pubmed/15280919
http://dx.doi.org/10.1038/sj.bjc.6602056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364791/
https://www.ncbi.nlm.nih.gov/pubmed/15280919
http://dx.doi.org/10.1038/sj.bjc.6602056

Ejemplares similares